Last Updated : January 29, 2025
Details
FilesGeneric Name:
ripretinib
Project Status:
Complete
Therapeutic Area:
Gastrointestinal stromal tumours
Manufacturer:
Medison Pharma Canada Inc.
Brand Name:
Qinlock
Project Line:
Reimbursement Review
Project Number:
PC0265-000
Tumour Type:
Gastrointestinal
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.
Fee Schedule:
Schedule A
Indications:
For the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | September 16, 2021 |
|---|---|
| Call for patient/clinician input closed | November 05, 2021 |
| Clarification: - Patient input submission received from CanCertainty and GIST Sarcoma Life Raft Group Canada (âLRGCâ) | |
| Submission received | October 15, 2021 |
| Submission accepted | October 29, 2021 |
| Review initiated | November 01, 2021 |
| Draft CADTH review report(s) provided to sponsor for comment | January 20, 2022 |
| Deadline for sponsors comments | January 31, 2022 |
| CADTH review report(s) and responses to comments provided to sponsor | February 25, 2022 |
| Expert committee meeting (initial) | March 09, 2022 |
| Draft recommendation issued to sponsor | March 22, 2022 |
| Draft recommendation posted for stakeholder feedback | March 31, 2022 |
| End of feedback period | April 14, 2022 |
| Final recommendation issued to sponsor and drug plans | April 28, 2022 |
| Final recommendation posted | May 16, 2022 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | May 12, 2022 |
| CADTH review report(s) posted | August 25, 2022 |
Files
Last Updated : January 29, 2025